Dr. Jun Ishihara is a Lecturer (equivalent to Assistant Professor in the USA) in the Department of Bioengineering at Imperial College London, starting in July 2020. The Ishihara laboratory works in the field of protein engineering, with research foci in cancer immunotherapy, autoimmunity, and regenerative medicine.
Ishihara received his PhD in stem cell biology from the University of Tokyo. Ishihara then conducted postdoctoral training in the laboratory of Jeffrey Hubbell first at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland from 2014 to 2016 and then at the University of Chicago from 2016 to 2020 when the laboratory relocated to the Pritzker School of Molecular Engineering. Ishihara developed novel technologies in the field of immuno-engineering in order to improve current drugs and discover new drugs. He has developed novel approaches to cancer immunotherapy that achieve local cancer immunotherapy by targeting the tumour microenvironment. These technologies improve both safety and efficacy of cancer immunotherapy. Ishihara also developed technologies to treat autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Ishihara also works in the field of regenerative medicine. He has developed novel approaches to deliver growth factors efficiently to the wound site in order to promote wound healing.
Ishihara has co-authored 17 scientific papers and 14 patents, with publications in Nature Biomedical Engineering, Science Translational Medicine, Science Advances, Blood and Nature Communications. Ishihara is also a co-founder of Arrow Immune Inc., which is focused on translating cancer immunotherapy technologies to the clinic, and ScienceLounge LLC., which runs a science bar in Tokyo for science outreach.
Dr. Ishihara's research publications can be found on Google Scholar https://scholar.google.com/citations?user=lAoKMNgAAAAJ&hl=en
et al., 2020, Enhanced lymph node trafficking of engineered IL‐10 suppresses rheumatoid arthritis in murine models, Arthritis & Rheumatology, ISSN:2326-5191
et al., 2020, Prolonged residence of an albumin–IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis, Nature Biomedical Engineering, ISSN:2157-846X
et al., 2020, Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours, Nature Biomedical Engineering, Vol:4, ISSN:2157-846X, Pages:531-543
et al., 2019, Conferring extracellular matrix affinity enhances local therapeutic efficacy of anti-TNF-α antibody in a murine model of rheumatoid arthritis, Arthritis Research and Therapy, Vol:21, ISSN:1478-6354, Pages:1-10
et al., 2019, Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy, Science Advances, Vol:5, ISSN:2375-2548, Pages:1-15